Cancer drugs: high price, uncertain value.
Level V
Where this comes from
- Record sourced from PubMed, PMID 28978508.
- Also identified by DOI 10.1136/bmj.j4543 and PMC identifier 5695518.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A study published in The BMJ this week shows how most new cancer drugs are failing to deliver any clinically meaningful benefit. It’s time for Europe to raise the evidence bar before market approval, finds <b>Deborah Cohen</b>
Medical subject headings
- Antineoplastic Agents
- Antineoplastic Agents/economics
- Antineoplastic Agents/therapeutic use
- Cost-Benefit Analysis
- Drug Approval
- Drug Approval/legislation & jurisprudence
- Drug Costs
- Drug Costs/legislation & jurisprudence
- Drug and Narcotic Control
- Europe
- Humans
- Treatment Outcome